Pfizer Lawsuit: Novo Nordisk Bid Against Metsera Blocked
Pfizer Sues Novo Nordisk, Metsera, Alleging Illegal Bid too Derail Acquisition
WILMINGTON, Del. – Pfizer has filed a lawsuit in the Delaware Court of Chancery against Novo Nordisk and its subsidiary, Metsera, alleging a breach of their merger agreement and asserting that Novo Nordisk’s competing offer for Biopharma Services is an illegal attempt to stifle competition. The suit claims Novo Nordisk’s proposal is a deliberately structured maneuver to evade antitrust scrutiny and is unlikely to be completed due to significant regulatory hurdles.
The legal action centers around Pfizer’s previously announced agreement to acquire Biopharma Services for $125 million.Pfizer contends novo Nordisk’s subsequent offer,presented as a “superior proposal,” is a calculated effort to disrupt the deal and unlawfully consolidate its dominant market position in contract development and manufacturing. This dispute arrives as Novo Nordisk experiences unprecedented demand for its weight-loss drug Wegovy and diabetes medication Ozempic, increasing scrutiny of its expansion strategies. The outcome of this case could substantially impact the competitive landscape of the biopharmaceutical manufacturing sector and the future of Biopharma Services.
According to the lawsuit, novo Nordisk’s offer “is not reasonably likely to be completed due to its significant regulatory risk.” Pfizer further alleges the offer “is an illegal attempt by a company with a dominant market position to suppress competition and uses an unprecedented structure designed to deliberately evade antitrust review.”
The complaint details concerns that Novo nordisk’s proposed structure is intentionally designed to avoid a thorough antitrust review, potentially allowing the company to gain an unfair advantage in the market. Pfizer is seeking legal intervention to enforce the original merger agreement and prevent Novo Nordisk from undermining the transaction. The case is being closely watched by industry analysts who anticipate it could set a precedent for future acquisitions in the rapidly evolving biopharmaceutical space.